
Schrödinger taps AI to speed drug discovery (Sponsored)
Robert Abel, chief scientific officer at Schrödinger, says advanced computational tools are changing the pace and accuracy of drug discovery. In a recent episode of The Top Line podcast, Abel outlined three areas where AI and machine learning are making the greatest impact: understanding disease biology, predicting protein structures and designing drug molecules. Schrödinger’s platform uses physics-based simulations alongside AI to evaluate millions of molecules in days, compared with the thousands traditionally synthesized in a year.
Abel pointed to real-world results…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.